Brought to you by:
Combining aspirin with rivaroxaban reduces risk equally in presence or absence of diabetes
In stable atherosclerosis, a combination of aspirin plus rivaroxaban provided a similar relative degree of benefit on coronary, cerebrovascular and peripheral endpoints in patients with and without diabetes, a prespecified analysis of the COMPASS trial has shown. It also noted…
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with aspirin alone. The VOYAGER PAD study was…